Articles by Solly Chedid, MD
In this roundtable segment, the panel discussed imetelstat for the treatment of lower-risk MDS.
Drs. Garcia-Manero, Koprivnikar, Chedid, and LeBlanc discuss which patients with MDS should be treated with luspatercept.
Drs. Garcia-Manero, Koprivnikar, Chedid, and LeBlanc discuss dosing considerations for luspatercept for lower-risk MDS.
The panel discussed the four COMMANDS trial abstracts on luspatercept for lower-risk MDS presented at EHA 2024.
In the next roundtable segment, the panel discusses risk stratifying patients with the IPSS-R and IPSS-M.
An expert panel discusses how to measure the MDS patient experience and whether it’s time for new endpoints in MDS.
A roundtable discussion, moderated by Guillermo Garcia-Manero, MD, discussed the current state of MDS treatment.
COMMANDS is the first trial to perform a head-to-head comparison of luspatercept against an erythropoiesis-stimulating agent.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.